Longevity Research

{
  "result": " **Executive Summary**\n\nThis tick, the Gonka Labs swarm laid the methodological foundation for a strictly human-centric investigation of the mTORC1–autophagy–inflammation axis, a pathway hypothesized to be a central lever in healthy aging. With 123 entities now catalogued but **zero validated causal relations** established, the cycle focused on locking a three-track triangulation strategy rather than generating immediate findings. Four hypotheses were updated, refining how genetic variation in *TSC2* and *RPTOR*, low-dose rapalog exposure, and clinical biomarker trajectories might jointly explain circulating levels of IL-6 and GDF-15—two inflammatory markers tightly linked to aging and mortality.\n\nThe most compelling development is the design of a *de novo* low-dose rapalog dose–response surface (0.1–5 nM rapamycin/everolimus) in ancestry-diverse human iPSC-derived macrophages, paired with multi-ancestry proteogenetic Mendelian randomization. The biological model is straightforward: mTORC1 acts as a cellular nutrient sensor, and when chronically overactive—as is common in aging—it suppresses autophagy, the cell’s recycling and damage-clearance program, while promoting sterile inflammation. By gently inhibiting mTORC1, either through inherited differences in *TSC2* or *RPTOR* protein abundance or through sub-immunosuppressive drug concentrations, we hypothesize that autophagic flux (tracked via LC3-II/p62 turnover with bafilomycin clamp) will recover, thereby reducing secreted IL-6 and GDF-15. If this transfer function holds, it would connect nutrient sensing, cellular housekeeping, and systemic “inflammaging” through a single, pharmacologically tractable pathway.\n\nCurrent evidence strength is entirely prospective. The framework intentionally excludes non-human animal models and unfocused literature scraping, relying instead on three human-provenance tiers: genetic instrumental variables across European, East Asian, and African ancestries; in vitro dose-response in human macrophages; and clinical pharmacokinetic/pharmacodynamic trajectories from renal transplant and TSC patients. While these tiers maximize translatability, none have yet produced validated relations, and recent automated additions to the knowledge base include unrelated clinical studies—underscoring why the swarm has narrowed extraction to these structured tracks. Consequently, confidence in any specific causal edge or dosing recommendation is currently nil, even though the broader mTORC1–longevity hypothesis enjoys substantial prior support.\n\nOutstanding questions will drive the next tick. Do *TSC2* and *RPTOR* blood protein quantitative trait loci show ancestry-specific causal effects on IL-6 and GDF-15, or do they share a single genetic architecture across populations (posterior probability PP.H4 > 0.8)? Is the macrophage dose-response surface linear, threshold, or hormetic, and does autophagy restoration strictly precede cytokine suppression? Can drug-exposure metrics from immunosuppressed patient cohorts be safely down-scaled to pro-longevity paradigms? Next, the swarm will execute the multi-ancestry colocalization, process the autophagy-flux clamp experiments, and run the quantitative meta-regression of drug exposure against longitudinal inflammatory biomarkers. We remain hopeful that this triangulation will eventually yield actionable, ancestry-aware insights, but the direction remains strictly hypothetical and unvalidated.\n\n**Disclaimer:** These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}